Telesis Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 27th of September, 2024.
47 hedge funds and large institutions have $92.9M invested in Telesis Bio, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 9 closing their positions.
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
9% more funds holding
Funds holding: 43 → 47 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
50% less capital invested
Capital invested by funds: $187M → $92.9M (-$93.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$15.5M |
| 2 |
OAM
Ophir Asset Management
Sydney,
Australia
|
+$3.35M |
| 3 |
PM
Penbrook Management
New York
|
+$1.21M |
| 4 |
Goldman Sachs
New York
|
+$1.11M |
| 5 |
State of Tennessee, Department of Treasury
Nashville,
Tennessee
|
+$433K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$8.54M |
| 2 |
PVI
Pura Vida Investments
New York
|
-$6.18M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$6.08M |
| 4 |
PA
Perceptive Advisors
New York
|
-$4.59M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.21M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
M&T Bank
Buffalo,
New York
| – | -$129K | -664 | Closed |
|
|
KC
52
KCL Capital
New York
| – | -$110K | -566 | Closed |
|
|
TWC
53
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$71.4K | -433 | Closed |
|
54
UBS Group
Zurich,
Switzerland
| – | -$31K | -157 | Closed |
|
|
T
55
TCWP
Beachwood,
Ohio
| – | +$152 | +1 | New |
|
56
Daiwa Securities Group
Tokyo,
Japan
| – | +$758 | +5 | New |
|
TBIO Hedge Fund Activity: Q1 2022 in Review
47 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Telesis Bio, Inc. Common Stock (TBIO) for Q1 2022, worth a combined $92.9M — down 50% from $187M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TBIO positions and 9 closed out — a net gain of 4 holders — while 16 added to existing stakes and 13 trimmed.
The largest buyer was Franklin Resources, adding an estimated $15.5M. The largest seller was Millennium Management, cutting an estimated $8.54M.
- 47 institutional investors held Telesis Bio, Inc. Common Stock (TBIO) as of Q1 2022, up from 43 in Q4 2021.
- Funds reported $92.9M of Telesis Bio, Inc. Common Stock stock for Q1 2022, down 50% quarter-over-quarter.
- 13 funds opened new Telesis Bio, Inc. Common Stock positions in Q1 2022 and 9 closed out, a net change of +4 holders.
- The largest Telesis Bio, Inc. Common Stock buyer in Q1 2022 was Franklin Resources, an estimated $15.5M added.
- The largest Telesis Bio, Inc. Common Stock seller in Q1 2022 was Millennium Management, an estimated $8.54M sold.
Based on aggregated 13F filings for Q1 2022.